SCHEMBL20394502

SCHEMBL20394502

FC(F)(F)Oc1ccccc1-c1cccnc1Oc1ccc(C(F)(F)F)nc1

nearest known ligand 0.40

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ PDE10A Q9Y233 3/20 0.39
▸ DRD1 P21728 2/20 0.39
▸ P2RY1 P47900 2/20 0.38
▸ P2RY14 Q15391 2/20 0.38
▸ SLC40A1 Q9NP59 1/20 0.38
▸ P2RY2 P41231 1/20 0.37
▸ SCN9A Q15858 3/20 0.37
▸ GPBAR1 Q8TDU6 1/20 0.36
▸ RORC P51449 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18661517 0.88 PDE10A (0.46) PDE10A
SCHEMBL20394410 0.86 GRM5 (0.41) NPSR1PDE10ASCN9ARORC
SCHEMBL20394435 0.84 FEN1 (0.40) PDE10AP2RY1
SCHEMBL20394188 0.83 MAOB (0.39) PDE10ASCN9A
SCHEMBL20394456 0.82 GRM5 (0.39) NPSR1PDE10A
SCHEMBL20394463 0.82 PDE10A (0.38) PDE10ASCN9A
SCHEMBL20394437 0.82 PDE10A (0.39) POLBPDE10AP2RY1SCN9A
SCHEMBL20394300 0.82 FEN1 (0.40) PDE10A
SCHEMBL18661504 0.82 PDE10A (0.43) PDE10AGPBAR1
SCHEMBL20394338 0.82 PDE5A (0.43) PDE10AGPBAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3351533-B1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2025-07-23 — — EP disclosed
US-10647675-B2 Biaryl derivative and medicine containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2020-05-12 — — US disclosed
US-10647675-B2 Biaryl derivative and medicine containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2020-05-12 — — US disclosed
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2019-02-21 — — US disclosed
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2019-02-21 — — US disclosed
EP-3351533-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2018-07-25 — — EP disclosed
EP-3351533-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2018-07-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647675-B2 Biaryl derivative and medicine containing same MAN2B1, CBR3, MANBA POLB 1481/4885NPSR1 1862/4885PDE10A 4605/4885
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME MAN2B1, CBR3, MANBA POLB 1481/4885NPSR1 1862/4885PDE10A 4605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback